Bioreactors Market Projected To Exhibit High Growth Rate Owing To Rising Adoption Of Cell Therapies

 Bioreactors Market

The bioreactors market has witnessed significant growth in recent years due to increasing demand for biopharmaceutical products such as vaccines, antibodies, and recombinant proteins produced using cell culture techniques. Bioreactors are vessel systems that provide the best possible environment to grow and manipulate cells for drug discovery and development. Growing research activities in the fields of cell therapy, tissue engineering, and gene therapy are fueling the adoption of various sized bioreactors for manufacturing living cells or tissues. Although conventional stainless steel bioreactors continue to dominate the market, single-use biosensors are rapidly gaining popularity to avoid the high costs and risks of cross-contamination associated with conventional systems.

Global Bioreactors Market is estimated to be valued at US$ 23.62 Bn  in 2024 and is expected to exhibit a CAGR of 11%  over the forecast period 2024 to 2030.


Market Drivers

Increasing commercialization of cell therapies for the treatment of cancer and other chronic diseases is a major market driver. Bioreactors allow for cost-effective production of cell therapies at commercial scale.

Growing R&D investments by pharmaceutical and biotechnology companies in the development of antibody-based drugs and vaccines will also augment the demand for bioreactors in the coming years.

Market Restraints

High costs associated with single-use bioreactors limit their widespread adoption, especially in price-sensitive developing markets. Additionally, the absence of trained professionals and limited biomanufacturing expertise in emerging countries pose a major challenge for market growth.

Segment Analysis
The Bioreactors Market Growth can be segmented into mammalian cell bioreactors, microbial bioreactors, insect cell bioreactors, and plant cell bioreactors. The mammalian cell bioreactors segment dominated the market in 2020 due to extensive use of mammalian cell lines like Chinese hamster ovary (CHO) for recombinant protein production. These mammalian cells have the ability to conduct post-translational modifications, making them suitable for therapeutic protein production. This segment is expected to continue its dominance over the forecast period owing to increasing demand for biologics like monoclonal antibodies produced in mammalian cells.

Global Analysis
Regionally, North America dominated the global bioreactors market in 2020 due to significant investments in R&D activities for cell-based research by pharmaceutical companies and research institutes in the region. The Asia Pacific region is expected to grow at the fastest rate during the forecast period owing to increasing penetration of global players into emerging Asian countries, rising awareness, and improving healthcare infrastructure in the region. China is anticipated to be the fastest growing country due to expansion of pharmaceutical industries and presence of major local players. Additionally, the region constitutes over 60% of the world's population, representing a lucrative target patient pool for various diseases.

Key Takeaways

Key players operating in the bioreactors market are Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton Dickinson and Company, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others. These players are focusing on new product launches and strategic collaborations to expand their market share.

The rising demand for personalized medicines and regenerative therapies represents a significant growth opportunity for bioreactor manufacturers. Additionally, improvements in cell culture media and process technologies will accelerate the commercial production of cell and gene therapies.

North America currently dominates the global bioreactors market. However, Asia Pacific is expected to witness the highest growth during the forecast period driven by increasing funding for bioprocessing infrastructure and growing adoption of bioprocessing techniques in China, India, and Southeast Asian countries.

Explore more related article on this topic: https://www.newswirestats.com/the-growing-bioreactors-market-demand-analysis/